60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
August 30, 2023 07:32 ET | Sixty Degrees Pharmaceuticals
Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
August 22, 2023 07:31 ET | Sixty Degrees Pharmaceuticals
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individualsTafenoquine...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
August 15, 2023 07:31 ET | Sixty Degrees Pharmaceuticals
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects
July 31, 2023 07:59 ET | Sixty Degrees Pharmaceuticals
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering
July 14, 2023 12:39 ET | Sixty Degrees Pharmaceuticals
WASHINGTON, July 14, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), specialists in developing and marketing medicines for infectious...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering
July 12, 2023 12:29 ET | Sixty Degrees Pharmaceuticals
WASHINGTON, July 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Awarded U.S. Patent Covering Tafenoquine for Treatment of COVID-19 and Other Lung Infections
April 26, 2023 07:34 ET | Sixty Degrees Pharmaceuticals
Patent provides exclusive use through 2040 of tafenoquine for treatment of COVID-19 and other lung infections. Tafenoquine is the active molecule in 60P’s FDA-approved drug for malaria prevention,...